Certain types of glaucomas do not respond to conventional trabeculectomy; they are named refractory glaucomas. They are notorious and often recurrent. Examples include: childhood, neovascular, uveitic, traumatic, glaucomas with wide conjunctival scars, post-vitrectomy, post-keratoprosthesis, post-keratoplasty, ciliary block, recurrent and glaucoma in aphakic and pseudophakic eyes. Some of those glaucomas require specific medical management like uveitic glaucoma. However, surgical intervention is ultimately needed in most of cases. Different surgical strategies include: antimetabolites-assisted trabeculectomy, drainage implants, cyclodestructive surgeries and other approaches. This review article will discuss the current management strategies for refractory glaucomas and the application of those treatment modalities to the specific glaucoma types.
Certain glaucomas do not expect to respond well to conventional trabeculectomy, they are collectively named Refractory glaucomas. Potential types are neovascular, uveitic, traumatic, glaucomas with wide conjunctival scars, childhood and juvenile, post-vitrectomy, post-keratoprosthesis, post-keratoplasty, ciliary block glaucoma, recurrent, glaucoma in aphakic and pseudophakic eyes 1, 2 . -Trans-scleral diode -Trans-scleral micropulse diode cyclo G6 -Endoscopic -High intensity focused ultrasound Pharmacological -Anti-glaucoma drugs -Antimetabolites -Anti-VGEF -Amniotic membrane -Ologen implant Combined approaches www.jors.js.iknito.com
Management options

Glaucoma drainage devices (GDD)
Use of setons to "Wick" aqueous from the anterior chamber dates back to 1906, with the use of horse hair to drain aqueous through a paracentesis. Various materials, including suture, glass, metals, plastic, and biologic material were used and ultimately failed due to problems with inflammation, fibrosis, and infection 3 . In the 1970s, Molteno pioneered development of a shunt, with a plate implanted posterior to the limbus and connected to the anterior chamber by a long silicone tube 4, 5 . . Flow-restrictive implants were developed in order to avoid problems associated with early postoperative hypotony. An implant with a pressuresensitive slit opening was described in 1976 by Krupin (no longer available). AGV was introduced in 1993. The valve is comprised of 2 thin silicon elastomer membranes positioned in a venturi-shaped chamber. Different models include polypropylene plates (single-, doubleplate, and pediatric), silicone plates (single-, double-plate, and pediatric), and a porous polyethylene plate. The silicone single-plate model (FP-7) has been popular among clinicians. AGV is the only available resistance glaucoma drainage device 7, 8 . The indications for valve implantation are refractory glaucomas, and perhaps as a primary surgery 9, 10 .
Cyclodestructive procedures
Betti introduced cyclocryotherapy in 1950. Then it was the era of cyclophotocoagulation (CPC). In 1961, Weekers was the first to use light energy as a means of cyclodestruction. Trans-scleral xenon arc photo-coagulation over ciliary body lowered IOP. In 1985 Beckman used ruby laser for cyclo-ablation. Nd:YAG CPC is 1064nm in the infrared spectrum was then used. Nowadays, diode laser is the most commonly used laser for cyclophotocoagulation 11, 12 .
Trans -scleral cyclophotocoagulation (TSCPC)
Diode laser 810nm applied through the sclera targets and destroys the melanin-containing pigmented ciliary epithelium resulting in decrease aqueous production. Other postulated mechanisms of action include ciliary body ischemia and uveoscleral flow enhancement 13, 14 . TSCPC is indicated in refractory glaucomas regardless the visual potential [14] [15] [16] [17] [18] . The G-probe is placed with its edge at the limbus. The initial settings are 1.500mW for 2 seconds with a total of 24 spots for the 360° treatment sparing the 3:00 and 9:00 clock positions. Some surgeons treat 270° sparing the upper nasal quadrant. Treatment is guided by the audible "pop" sound that indicates tissue explosion within the ciliary body. Increase the power by 100mW till the audible pop is reached, then reduce 100mW below that power setting 19 . After treatment, The IOP reduction is variable, 54% to 92% of treated eyes attain IOP below 21mmHg. Retreatment rate is up to 30% 20, 21 . Rotchford and co-workers 22 evaluated the effects of diode CPC in patients with good (≥ 20/60) visual acuity. The results showed that 73.5% of patients had a final IOP of 16mmHg or less and that only 30.6% lost 2 or more Snellen lines. To compare, in the Tube Versus Trabeculectomy (TVT) study, 63.9% of patients in the tube shunt group and 63.5% of patients in the trabeculectomy group had an IOP of 14mmHg or less. Forty-six (46%) of the tube shunt patients and 43% of the trabeculectomy patients lost 2 or more lines of Snellen visual acuity 23 . Complications include surface burns, uveitis, atonic pupil, hyphema and vitreous hemorrhage in eyes with neovascular glaucoma (NVG), hypotony and phthisis bulbi 19, 24 .
Endoscopic cyclophotocoagulation (ECP)
In this technique, the secretory ciliary epithelium is coagulated under direct www.jors.js.iknito.com visualization using a Xenon-illuminated microscope. It is desirable that the patient is pseudophakic or aphakic; either pre-existing or achieved at the time of surgery (Phaco-ECP). ECP is performed using the Uram E2 ophthalmic endoscopic laser (Endo Optics, Little Silver, N,J). This consists of a 20-guage endoscopic probe containing four elements: (1) 175 W Xenon light source, (2) HeliumNeon laser aiming beam, (3) Finer optic cable for imaging, and (4) 810 nm diode thermal laser. ECP is performed through a clear cornea or pars plana approach. In the former, anterior vitrectomy is not required. A pars plana approach may be useful in eyes that have previous vitrectomy or at the time of vitrectomy. Treatment is applied in a "painting" technique, starting at the top of the ciliary processes and progressing toward their bottoms 25 . Laser settings: treat 180 to 360 degrees, continuous settings, about 3 seconds for slow whitening, 250-900mW (up to a maximum of 2.0W) 11 . Encouraging results have been reported with refractory glaucomas and combined with cataract surgery as a primary surgical treatment, however retreatments are occasionally needed [26] [27] [28] [29] [30] [31] [32] . ECP has apparent advantages including a relatively short learning curve, quick, well-tolerated, and repeatability
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. Fibrinous uveitis is the main complication after ECT (up to 51%). Other complications include, hyphema, IOP spikes, choroidal detachment, retinal detachment, reduced vision, corneal decompensation, and cystoid macular edema (CME) 33, 34 . In comparison to TSCPC, ECP is an invasive procedure, though it is a disadvantage, it allows for direct visualization of the ciliary processes with titration of treatment and much less tissue destruction compared to TSCPC 35 . Both achieved a desired IOP reduction (21mmHg with or without medications) in 67.6% of the ECP group and 30.8% of the TSCPC group after 6 months in penetrating keratoplasty glaucoma. In comparison to tube surgery, in a prospective study performed on pseudophakic eyes, at 24 months, 70.59 % and 73.53% achieved the desired IOP for AGV and ECP groups, respectively 36 .
Micropulse trans -scleral cyclophotocoagulation (MP-TSCPC)
The cyclo G6 with the MP3 probe, (figure 1), applies a series of short (microsecond), repetitive bursts of energy that effectively confines the thermal effect to the absorbing tissue. The micropulse delivery mode includes on and off cycles, allowing energy to build up in the targeted pigmented tissues, eventually reaching the coagulative threshold.
The micropulse duty cycle on the laser is set to 31.3% and the power is set to 2W 
High intensity focused ultrasound (HIFU)
The EyeOP1 is a portable device that consists of a control module and a probe that uses an HIFU technology at 21MHz. The rationale of the device is to perform circular ultrasound cyclocoagulation (UC3) in a single step. A ring containing six active piezoelectric elements is inserted in a coupling cone 46, 47 . The first clinical pilot study using miniaturized HIFU in refractory glaucoma was conducted by Aptel and co-workers 47 in 2011. They documented a surgical success rate of 83.3%, a significant reduction in IOP from a mean pre-operative value of 37.9 +/-10.7mmHg to 26.3 +/ 5.1mmHg at 3-month follow-up. The EyeMUST1 Study was a 12-month open-label multicenter prospective study conducted to determine the efficacy and safety of UC3 48 . Primary outcome was IOP reduction at 12 months. This was achieved in 57.1% of the patients. Success was lower in patients with secondary glaucoma compared to patients with primary open-angle glaucoma (45.0 vs 78.6%). Mean IOP reduction at 6 months was 30.2%, and at 1 year was 36.0%. However, this study found no reduction in IOP-lowering medications. Other studies have been conducted to evaluate the clinical outcomes of UC3 in refractory glaucoma 48, 49 . Overall, it seems that UC3 tends to have lasting efficacy in controlling the IOP during the first year, with a success rate ranging from 48% to 83.3% 50, 51 .
Pharmacological -assisted surgeries Antimetabolites
Both 5-fluorouracil (5-FU) and mitomycin C (MMC) are used to inhibit fibroblast proliferation and enhance surgical success. Their use has become a standard clinical practice, particularly in complex high-risk cases 52, 53 .
5-Fluorouracil
Intraoperative: 25 or 50mg/mL undiluted solution on a filter paper or a sponge and left for 5 minutes. Postoperative: 0.1ml injection of 50mg/ml undiluted solution adjacent to the bleb. Repeat injections are often necessary. Mitomycin-C Intraoperative: diluted solution 0.1-0.5mg/ml for 1-5 minutes on a filter paper or a sponge. Postoperative injection of 0.1ml of 0.02mg/ml solution adjacent to but not into the bleb. A meta-analysis comparing intraoperative MMC to 5FU showed greater percentage of IOP reduction achieved with MMC
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. Adjunctive MMC to tube surgery proved beneficial 52,55
Anti-vascular endothelial growth factor (VEGF)
The role of the vascular endothelial growth factor in rubeotic glaucoma is well documented. Additionally, it plays an important role in wound conjunctival healing. Conjunctival VEGF is upregulated in presence of inflammatory cytokines such as TGF-B1, interleukin 1ß, and interleukin-4 56 . Subconjunctival injection of bevacizumab after trabeculectomy in a rabbit model improved bleb morphology, and reduced vascularity and scarring 57 . Human studies have shown that MMC is superior to anti-VEGF in terms of IOP control 58, 59 . 
Specific forms of refractory glaucomas Childhood glaucomas
Childhood glaucomas include a wide variety of conditions which result in elevated intraocular pressure and optic nerve damage. They are classified into: (1) Primary congenital glaucoma (newborn and infantile), when an isolated idiopathic developmental abnormality of the anterior chamber angle exists. (B) Glaucomas associated with congenital anomalies; aqueous outflow is reduced due to congenital ocular or systemic disorder, and (C) Acquired glaucoma; the outflow impairment is the result of acquired ocular disease or systemic abnormality 53 . Medical treatment is frequently needed as a temporary measure to lower the IOP before surgery or as an adjunct therapy after partially successful surgical procedures. Medications are occasionally the first-line for some cases (e.g. uveitis-related, glaucoma after cataract removal). Brimonidine should be avoided in young children 70 . Surgery by a trained surgeon is the ultimate management in the majority of cases. The first operation is usually the best chance. Options include: (1) Angle surgery; goniotomy, trabeculotomy (conventional or circumferential) is the procedure of choice. . AGV surgery with variable success rates (20.6%-70%) 93, 94 . AGV has been combined with intravitreal bevacizumab injection with encouraging results 95 , and has been implanted at the time of pars plana vitrectomy [96] [97] [98] . TSCPC with and without the use of anti-VEGF has been shown to be effective in lowering IOP and relieving pain in advanced cases of NVG 99, 100 . When compared to AGV implantation in a randomized controlled trial, no significant difference was found in the success rate at 24 months between the diode cyclophotocoagulation (61.18 %) and AGV valve implantation (59.26 %) in NVG treatment 101 .
Glaucoma after silicone oil injection 5.9% to 56% of cases got IOP elevation after silicone oil injection, it may be transient or permanent. In the early postoperative phase, it may be related to pupillary block, inflammation, preexisting glaucoma, and silicone oil migration into the anterior chamber. In the intermediate and late phases, it may be due to infiltration of the trabecular meshwork by emulsified silicone oil, steer response, www.jors.js.iknito.com synechial closure, and rubeosis 102, 103 . Inferior peripheral iridotomy at the time of surgery prevent pupillary block in aphakic and pseudophakic eyes 104 . Cases refractory to medical treatment benefit from silicone oil removal with or without glaucoma surgery 105, 106 .
Trabeculectomy with antimetabolites has a high rate of failure. Aqueous shunts are more likely to succeed. The implant can be positioned superiorly or inferiorly to avoid silicone oil migration. Pars plana insertion of the tube is another option. Cyclodestructive procedures are another option 107, 108 . Selective laser trabeculoplasty (SLT) has been used with encouraging results in eyes with persistent IOP elevation after silicone oil evacuation 109 .
Uveitic glaucoma (UG)
Glaucoma occurs in around 20% of all patients with chronic uveitis. Higher rates are reported in those with rheumatoid arthritis-associated iridocyclitis, Fuchs heterochromic iridocyclitis (27%), sarcoidosis (34%), herpes simplex keratouveitis (54%), zoster uveitis (38%), Lyme-associated uveitis, cancer-associated uveitis 13 , juvenile idiopathic arthritis (12-35%), Behçet's disease, pars planitis, sympathetic ophthalmia, and syphilis 110 . About 30% of eyes with UG may require surgery after initial medical treatment [111] [112] [113] . There is a consensus that the surgical success rate of filtering surgery is lower for eyes with UG compared with POAG. As a rule, suppression of inflammation in the perioperative period significantly improves outcomes 114 . 121 , cyclophotocoagulation 122, 123 , and iridotomy 124 .
CONCLUSIONS
Refractory glaucomas constitute a group of disorders with pathologically elevated IOP causing optic nerve damage in which conventional trabeculectomy is less successful or even ineffective. 1-The common forms are: childhood, NVG, post-PPV, post-keratoplasty, uveitic, glaucoma in aphakic and pseudophakic eyes. 2-Medical treatment is effective in some cases, in conjunction with specific therapy. 3-The common surgical options are antimetabolites-assisted trabeculectomy, glaucoma drainage implants and cyclodestructive procedures. 4-There are tremendous improvements in the cyclodestructive techniques in the last few years with better outcomes.
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